GlassScriptPhysician profile
Lawrence Ira Garter
NPI 1174512990
$728.66
in general payments reported to CMS, 2019-2025
14 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $39.46 · 2022: $63.51 · 2023: $164 · 2024: $98.16 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160.09 | 2019-2025 | |
| Cranial Technologies, INC | $135.02 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $90.57 | 2019-2025 | Gardasil 9, Vaxelis, Enflonsia |
| Astrazeneca Pharmaceuticals LP | $79.99 | 2023-2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $45.90 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.28 | 2019-2023 | Elaprase |
| Sanofi-Aventis U.S. LLC | $29.72 | 2025 | |
| Biomarin Pharmaceutical INC. | $27.94 | 2025 | Voxzogo 1.2mg |
| Sobi, INC | $27.75 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.14 | 2020 | |
| Biogen, INC. | $19.62 | 2019 | |
| Neurelis, INC. | $19.26 | 2023 | Valtoco |
| Cipher Pharmaceuticals US LLC | $14.74 | 2025 | Natroba, Spinosad |
| Amneal Pharmaceuticals LLC | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Garter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.